SYNGENE.NSE logo

SYNGENE.NSE
Syngene International Ltd.

252
Loading...
Loading...
News
all
press releases
India-EU trade deal: OneSource Specialty, Syngene, Sigachi, other pharma stocks tank up to 19%; here's why
… lower input costs for Indian pharma companies sourcing specialised ingredients from … stocks. On BSE, OneSource Specialty Pharma (19%), Syngene International (11%), Sigachi … .41%), Wanbury Ltd (7%), Kwality Pharmaceuticals (5.67%), Supriya Lifescience (6% …
cityfalcon.com·2mo ago
News Placeholder
More News
News Placeholder
GSK Pharma to Procure 4.95 MWp Solar Power from CleanMax in Maharashtra
GlaxoSmithKline Pharmaceuticals (GSK Pharma ) will procure 4.95 MWp … , Syngene International, a Bengaluru-based pharmaceutical company, announced procuring renewable energy … February 2025, Mumbai-based Aarti Drugs partnered with Prozeal Green Energy …
cityfalcon.com·5mo ago
News Placeholder
India’s Healthcare Index Sinks After Trump’s Pharma Tariff Blow — SEBI Analyst Sees Risks For Gland, Biocon, Dr. Reddy’s
The analyst noted that Syngene, Piramal Pharma, and Zydus Lifesciences may be better positioned, as their contract manufacturing models and biologics portfolios are less susceptible to the tariff impact.
Stocktwits·6mo ago
News Placeholder
Trading Radar For August 21: Vedanta, Zee Entertainment, Clean Science, India Cements, Railtel Are On Stocks Watchlist
Gem Aromatics, Patel Retail, Shreeji Shipping Global, Vikram Solar, and Mangal Electrical Industries IPOs are currently open for subscription
Stocktwits·7mo ago
News Placeholder
Syngene International reports 11% revenue growth and 59% net profit surge in Q1
Syngene International, a Biocon subsidiary, reveals an 11% revenue increase to Rs 875 crore for the first quarter. Net profit jumps 59% to Rs 87 crore. Growth is attributed to research services and biologics manufacturing. Operations commenced at Unit III in Bengaluru. Preparations advance for the Bayview facility in the US.
cityfalcon.com·8mo ago
News Placeholder
Syngene Consolidates Ahead Of Q1 Earnings: SEBI RA Rohit Mehta Sees Potential Breakout Above ₹700
While past earnings have been positive, the stock trades at a high valuation and offers a low dividend payout
Stocktwits·8mo ago
News Placeholder
July Stock Themes: SEBI RA Rohit Mehta Flags Renewables, Pharma, Infra Sectors For Big Rotations
India's clean energy push, pharma transformation, and record capex plans are drawing investor focus heading into July, with key beneficiaries emerging across all three sectors.
Stocktwits·9mo ago
<
...
1
>

Latest SYNGENE.NSE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.